Pegpleranib Sodium(Pegpleranib Sodium) - 药物靶点：PDGFR_专利_临床

概要

基本信息

药物类型

适配体

别名

Fovista、Pegpleranib、DD50D2QKH1 (UNII code)

+ [6]

靶点

PDGFR

作用机制

PDGFR拮抗剂(血小板衍生生长因子受体拮抗剂)

治疗领域

遗传病与畸形眼部疾病其他疾病+ [1]

在研适应症-

非在研适应症

年龄相关性黄斑变性黄斑变性纤维化+ [3]

原研机构

Archemix Corp.

在研机构-

非在研机构

Ophthotech Corp. (New Jersey)

IVERIC bio, Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 239098577

来源: *****

关联

18

项与 Pegpleranib Sodium 相关的临床试验

NCT02859441 / Completed临床1/2期IIT

A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab

Background: People with Von-Hippel-Lindau (VHL) disease may experience significant vision loss as a result of retinal capillary hemangiomas (RCH), the most common and often earliest manifestation of VHL.
Objective: To investigate the safety and possible efficacy of combination investigational treatment with serial intravitreal injections of E10030, a PDGF-B antagonist, and ranibizumab, a VEGF-A antagonist, in participants with severe ocular VHL disease.
Design: Three participants with severe ocular VHL disease will receive the combination investigational treatment in one eye and will be followed for 104 weeks.
Primary Outcome: The safety of the combination investigational treatment, assessed by tabulation of adverse events reported through Week 52.

开始日期2017-01-23

申办/合作机构

National Eye Institute

NCT02387957 / Terminated临床2期

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.

开始日期2016-04-26

申办/合作机构

Ophthotech Corp. (New Jersey)

EUCTR2015-000519-42-IT / Not yet recruiting临床2期

Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 monthPhase 2a open label study of Fovista¿ (anti-PDGF therapy) administered in combination with anti-VEGF therapy - OPH1008

开始日期2015-12-15

申办/合作机构

IVERIC bio, Inc.

100 项与 Pegpleranib Sodium 相关的临床结果

登录后查看更多信息

100 项与 Pegpleranib Sodium 相关的转化医学

登录后查看更多信息

100 项与 Pegpleranib Sodium 相关的专利（医药）

登录后查看更多信息

7

项与 Pegpleranib Sodium 相关的文献（医药）

2023-01-01·International journal of nanomedicine

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.

Review

作者: Zhang, Feng ; Cao, Jiamin ; Xiong, Wei

Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

2021-12-01·Clinical & experimental ophthalmology3区 · 医学

Intravitreous treatment of severe ocular von Hippel–Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial

3区 · 医学

Article

作者: Hwang, Christopher K. ; Keenan, Tiarnan D. L. ; Cukras, Catherine A. ; Chittiboina, Prashant ; Pacak, Karel ; Wong, Wai T. ; Wiley, Henry E. ; Linehan, W. Marston ; Chew, Emily Y.

Abstract:

Background:

Treatment options for severe ocular von Hippel–Lindau (VHL) disease are limited. This trial evaluated preliminary safety and potential efficacy of combination intravitreous injection with ranibizumab, a vascular endothelial growth factor (VEGF) inhibitor, and E10030, a PDGF inhibitor, for eyes with VHL disease‐associated retinal hemangioblastoma (RH) not amenable or responsive to thermal laser photocoagulation.

Methods:

This was a prospective, single‐arm, open‐label phase 1/2 study, comprised of three adults with VHL‐associated RH and vision loss. Intravitreous injections of ranibizumab (0.5 mg) and E10030 (1.5 mg) were given unilaterally every 4 weeks in the study eye through 16 weeks, then every 8 weeks through 48 weeks. Supplementary standard care therapies were allowed without restriction after 40 weeks. The primary outcome was the ocular and systemic adverse effect profile at 52 weeks. Secondary outcomes included changes in best‐corrected visual acuity (BCVA), RH size, exudation, epiretinal proliferation and retinal traction, and need for ablative treatment of RH or ocular surgery at week 52.

Results:

Three participants each received nine injections prior to week 52 and were followed for 104 weeks. One participant manifested mild episodic ocular hypertension in the study eye. Change in BCVA in the study eye at week 52 for the three participants was −5, −12 and +2 letters. No reduction in RH size was measured at 52 weeks. Variable mild improvements in exudation in two participants at week 16 were not sustained through week 52.

Conclusions:

Combination intravitreous injection with ranibizumab and E10030 demonstrated a reasonable preliminary safety profile, but limited treatment effect.

2017-07-03·Expert opinion on emerging drugs2区 · 医学

Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration

2区 · 医学

Review

作者: Hussain, Rehan M ; Ciulla, Thomas A.

INTRODUCTION:

Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and genetic therapy strategies. Areas covered: Brolucizumab and abicipar pegol have smaller molecular size, facilitating higher concentrations and potentially longer duration than current anti-VEGF agents. Agents being combined with anti-VEGFs include OPT-302 (to inhibit VEGF-C and VEGF-D); pegpleranib and rinucumab (to inhibit platelet derived growth factor, PDGF - but both failed to show consistently improved visual outcomes compared to anti-VEGF monotherapy); and RG7716, ARP-1536 and nesvacumab (to activate the Tie-2 tyrosine kinase receptor, which reduces permeability). X-82 is an oral anti-VEGF and anti-PDGF being tested in phase 2 studies. Topical anti-VEGF ± anti-PDGF drugs under study include pazopanib, PAN-90806, squalamine lactate, regorafinib, and LHA510. Sustained-release anti-VEGF delivery treatments, such as the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot, Durasert, and ENV1305 aim to reduce the burden of frequent injections. Gene therapies with new viral vectors hold the potential to induce sustained expression of anti-angiogenic proteins via the retina's cellular apparatus, and include AVA-101/201, ADVM-202/302, AAV2-sFLT01, RGX314, and Retinostat. Expert opinion: There are many emerging anti-VEGF treatments that aim to improve visual outcomes and reduce the treatment burden of nAMD.

3

项与 Pegpleranib Sodium 相关的新闻（医药）

2023-05-01

·FierceBiotech

Astellas keeps the big buyouts rolling, inking $5.9B Iveric takeover ahead of FDA eye disease ruling

Astellas framed the deal to buy Iveric Bio as a way to further its focus on blindness and regeneration. The multibillion-dollar biotech buyouts keep on coming. Astellas Pharma is the latest drugmaker to get in on the act, agreeing to pay $5.9 billion to buy Iveric Bio and establish itself as a player in an emerging eye disease niche. Iveric is less than three months away from learning whether the FDA will approve avacincaptad pegol, a complement C5 protein inhibitor that reduced the rate of geographic atrophy (GA) progression in a phase 3 clinical trial. Patients with GA, a cause of irreversible loss of vision in patients with age-related macular degeneration (AMD), lacked treatments until recently, but the market is heating up fast. Apellis Pharmaceuticals won the first FDA approval for a GA drug, Syfovre, in February, and companies including AstraZeneca, Johnson & Johnson, Novartis and Roche are in pursuit. Iveric, a biotech formerly known as Ophthotech, is poised to be the first commercial rival to Apellis, though. That fact has caught Astellas’ attention. Astellas has agreed to pay $40 per share in cash to buy Iveric. The fee represents a 22% premium over Iveric’s closing price at the end of last week. That may seem light in the wake of the triple-digit premiums that GSK and Sanofi have paid recently for Bellus Health and Provention Bio, respectively, but it follows a steady rise in Iveric’s share price. The premium over Iveric’s March 31 share price is 64%. The willingness of Astellas to pay $5.9 billion for Iveric reflects the Japanese drugmaker’s desire to hit its 2025 sales target and need to add new growth drivers to offset the anticipated loss of revenue when the prostate cancer drug Xtandi loses patent protection in 2027. Astellas also framed the deal as a way to further its focus on blindness and regeneration. Cell and gene therapies are part of the strategy, but that side of the pipeline has stuttered, with enrollment in a phase 1 trial of GA candidate ASP7317 stopping for two years and a glaucoma prospect acquired in the Quethera buyout yet to reach the clinic. Buying Iveric will give Astellas a GA drug that could be approved by the time the deal closes in the third quarter and accelerate an expansion into ophthalmology by providing control of the commercial team and other infrastructure that the biotech has built up to support the launch. Earlier this year, Iveric said it was building a 120-person sales team that would include 50 to 70 field-based reps. The deal completes an impressive recovery for Iveric, which was on the ropes in 2017. Back then, a run of three clinical trial failures for Fovista sunk the biotech’s stock and wiped out the optimism generated when Novartis paid $200 million for ex-U.S. rights to the AMD asset. Yet, Iveric recovered, changing its name from Ophthotech and embarking on a GA strategy that culminates today in the Astellas buyout.

并购临床1期临床3期上市批准

2021-04-05

·BioSpace

Iveric Bio’s Co-Founder Leaves to Return to Venture Capitalist Role

IVERIC bio’s co-founder and Executive Chairman David R. Guyer is stepping down from his role to return to his first love – investing. He’ll make a return to his former role at SV Health Investors as a Venture Partner. In it from day one, Guyer has guided the company from the boardroom since the retinal disease company’s 2007 inception. Then named Ophthotech, Guyer also led as CEO from 2013-2017. Iveric has been through some highs and lows in Guyer’s time. After a somewhat promising Phase II combination trial, the company’s wet age-related macular degeneration (AMD) drug Fovista flopped badly in Phase III, failing to show any measurable benefit. Guyer had to make the tough call to cut 80% of staff, leaving its headcount at less than 50. From there, the company pivoted toward gene therapies, in-licensing a portfolio of eye disease-related treatments in development. This move led to the renaming of the Ophthotech to Iveric Bio, updating its Nasdaq symbol to the clever “ISEE” on the ticker. Iveric’s lead drug Zimura is a C5 inhibitor currently in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Zimura published positive Phase III results last fall and continues in a Phase II study for autosomal recessive Stargardt disease. “I am very excited about Iveric's phase 3 program of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration and look forward to continuing to serve the company as a senior advisor,” Guyer said. Guyer will remain a senior advisor to Iveric, without the weight of any executive powers. “As a co-founder, former Chief Executive Officer and most recently Executive Chair, David has been an integral part of Iveric Bio’s leadership, a trusted advisor and visionary in retinal medicine, and I sincerely thank him for his hard work and significant contributions to the Company,” stated Glenn P. Sblendorio, chief executive officer and president of Iveric Bio. “Iveric Bio's strong management team has evolved to the point where there is no longer a need for an Executive Chair,” Guyer added. “After more than 14 years on the Board, I feel that this is a good departure point such that I can return to my passion as a venture capitalist."

2017-03-02

·BioPortfolio

Ophthotech Corp OPHT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

Summary Ophthotech Corp Ophthotech is a biopharmaceutical company that provides developing therapeutics for agerelated macular degeneration. The company's products include Fovista, an antiplateletderived growth factor PDGF, Zimura an anticomplemente is a central component of the complement cascade that is supposed to be involved in the development of AMD. Ophthotech utilizes aptamer technology, a single strands of nucleic acid to targets such as PDGF, comparable to a monoclonal antibody. The company's Fovista is used to inhibit abnormal new blood vessel growth associated with wet AMD. Ophthotech is headquartered in New York, the US. Ophthotech Corp OPHT Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

抗体并购

100 项与 Pegpleranib Sodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB06325

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
黄斑变性	临床3期	比利时	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	丹麦	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	瑞士	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	土耳其	IVERIC bio, Inc.	2013-08-01
黄斑变性	临床3期	英国	IVERIC bio, Inc.	2013-08-01
Wet AMD	临床3期	美国	Ophthotech Corp. (New Jersey)	2013-08-01
Wet AMD	临床3期	阿根廷	Ophthotech Corp. (New Jersey)	2013-08-01
Wet AMD	临床3期	澳大利亚	Ophthotech Corp. (New Jersey)	2013-08-01
Wet AMD	临床3期	奥地利	Ophthotech Corp. (New Jersey)	2013-08-01
Wet AMD	临床3期	比利时	Ophthotech Corp. (New Jersey)	2013-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02859441 (Pubmed \| Clin Exp Ophthalmol) 人工标引	临床1/2期	希佩尔·林道综合征	3	E10030+ranibizumab	鹽糧繭蓋觸製壓網願製(製衊積顧鬱觸製夢範鬱) = One participant manifested mild episodic ocular hypertension in the study eye 鏇襯壓壓獵齋範鹹膚襯 (齋襯鏇範鹹糧夢構衊襯 ) 更多	不佳	2021-09-21
NCT01940887 (OPH1004, CTgov)	临床3期	Wet AMD	645	aflibercept+E10030+bevacizumab (E10030 + Bevacizumab or Aflibercept)	築夢簾繭糧糧窪範積鏇(製醖鬱構築顧襯鏇餘膚) = 積鹽蓋選襯網顧鬱淵獵膚蓋壓艱構憲範選衊窪 (艱膚積鏇夢衊繭簾衊襯, 餘壓鑰夢鑰鑰餘築鹹觸 ~ 衊觸選簾廠構遞鬱艱簾) 更多	-	2020-09-30
				aflibercept+E10030 sham injection+bevacizumab (Sham + Bevacizumab or Aflibercept)	築夢簾繭糧糧窪範積鏇(製醖鬱構築顧襯鏇餘膚) = 鏇選餘築齋鹽顧積膚構膚蓋壓艱構憲範選衊窪 (艱膚積鏇夢衊繭簾衊襯, 選夢積窪觸齋醖鹽艱築 ~ 衊製餘襯獵鑰積遞觸夢) 更多
NCT02214628 (CTgov)	临床2期	Wet AMD	101	Fovista (Fovista® (Anti-PDGF BB) Plus Anti-VEGF Simultaneous Regimen)	窪願積襯夢鹽鹹醖遞糧(艱廠選鬱鹽蓋遞繭積遞) = 簾夢夢醖鹹築衊艱憲襯夢鏇壓網壓積窪蓋範蓋 (襯顧壓鹽鏇襯艱繭簾鏇, 觸齋鹽淵壓壓艱網淵鏇 ~ 餘壓鹽範壓壓襯衊鹹鏇) 更多	-	2019-07-10
				Fovista (Fovista® (Anti-PDGF BB) Plus Anti-VEGF Pre-Treatment Regimen)	窪願積襯夢鹽鹹醖遞糧(艱廠選鬱鹽蓋遞繭積遞) = 繭繭醖積簾築簾衊糧範夢鏇壓網壓積窪蓋範蓋 (襯顧壓鹽鏇襯艱繭簾鏇, 淵繭糧築繭顧壓糧願鏇 ~ 廠醖願蓋醖淵繭鬱廠夢) 更多
NCT02387957 (CTgov)	临床2期	年龄相关性黄斑变性	63	Fovista®+Bevacizumab (Fovista® Plus Bevacizumab)	網餘繭構壓鬱觸鹹選鏇(蓋顧積鹽網膚構壓齋鹹) = 蓋遞鹹顧夢製壓醖壓鏇顧簾壓鑰觸顧構遞襯糧 (壓廠襯願鹽鏇鹹壓積遞, 鹽獵網膚廠蓋繭願鬱淵 ~ 鹹築遞構憲範繭襯願範) 更多	-	2019-03-05
				ranibizumab+Fovista® (Fovista® Plus Ranibizumab)	網餘繭構壓鬱觸鹹選鏇(蓋顧積鹽網膚構壓齋鹹) = 窪範醖願憲鹹鹽憲衊壓顧簾壓鑰觸顧構遞襯糧 (壓廠襯願鹽鏇鹹壓積遞, 製製觸鬱簾鏇襯餘糧築 ~ 鑰鏇鹹顧鑰夢鹽範獵窪) 更多
NCT01940900 (OPH1003, CTgov)	临床3期	Wet AMD	627	ranibizumab+E10030 (E10030 + Ranibizumab)	鬱餘廠廠觸鏇範築淵膚(廠遞願獵積糧遞鏇衊範) = 齋鹽窪製鑰壓獵鹽艱膚願餘願鹹艱淵鬱衊齋鏇 (襯艱鹽構鏇範糧鏇餘願, 艱選獵淵糧顧獵鹽襯窪 ~ 積壓醖夢築遞膚糧艱鑰) 更多	-	2018-08-15
				ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab)	鬱餘廠廠觸鏇範築淵膚(廠遞願獵積糧遞鏇衊範) = 襯壓繭鹹鏇醖選顧鏇築願餘願鹹艱淵鬱衊齋鏇 (襯艱鹽構鏇範糧鏇餘願, 積獵鹹製膚鏇鏇鹹製願 ~ 構襯夢簾鬱醖齋構簾鏇) 更多
NCT01944839 (OPH1002, CTgov)	临床3期	Wet AMD	619	ranibizumab+E10030 (E10030 + Ranibizumab)	積製糧醖築齋鹽窪鹽襯(範觸範廠遞鏇積遞窪夢) = 鹹衊膚醖選夢遞艱壓範淵齋夢夢鏇壓膚顧遞膚 (選鑰憲醖窪蓋鏇積餘構, 範選壓淵獵遞膚糧獵廠 ~ 廠構鑰鹽願襯鬱糧淵鏇) 更多	-	2018-08-10
				ranibizumab+E10030 sham intravitreal injection (Sham + Ranibizumab)	積製糧醖築齋鹽窪鹽襯(範觸範廠遞鏇積遞窪夢) = 鬱遞廠築顧範憲餘鹹鑰淵齋夢夢鏇壓膚顧遞膚 (選鑰憲醖窪蓋鏇積餘構, 獵淵構淵淵鑰壓製簾艱 ~ 衊獵艱製蓋願顧淵鏇繭) 更多
NCT01940887 (OPH1004, PipelineReview) 人工标引	临床3期	Wet AMD	640	Aflibercept+Avastin+Fovista	築窪窪壓窪廠鹽鑰願鏇(構構衊顧鑰鹹壓窪製鏇) = 壓醖夢繭簾積鑰鹹糧鑰醖夢膚壓鹽壓鏇鏇廠鏇 (築製壓艱艱顧廠願簾鏇 )	不佳	2017-08-15
				Aflibercept+Avastin+Placebo	築窪窪壓窪廠鹽鑰願鏇(構構衊顧鑰鹹壓窪製鏇) = 衊簾鬱遞鬱艱憲齋衊蓋醖夢膚壓鹽壓鏇鏇廠鏇 (築製壓艱艱顧廠願簾鏇 )
NCT01944839 (OPH1002, PipelineReview) 人工标引	临床3期	Wet AMD	621	Ranibizumab+Pegpleranib Sodium	遞願鹽選鹽積憲衊遞艱(構簾憲構鹹簾糧鑰蓋餘) = 鬱廠網願衊鬱淵糧積遞鹽鹽鹽憲築遞鑰製積夢 (築壓構夢餘願糧憲膚構 )	不佳	2016-12-12
				Ranibizumab+Placebo	遞願鹽選鹽積憲衊遞艱(構簾憲構鹹簾糧鑰蓋餘) = 築選觸衊醖壓衊獵願簾鹽鹽鹽憲築遞鑰製積夢 (築壓構夢餘願糧憲膚構 )
NCT01940900 (OPH1003, PipelineReview) 人工标引	临床3期	Wet AMD	627	Ranibizumab+Pegpleranib Sodium	獵遞遞鑰齋繭衊糧夢築(醖鏇鏇淵齋鏇範鑰觸齋) = 艱網鬱願鹹壓鬱簾製醖憲壓淵觸夢築遞鹹範鹽 (齋窪觸範鹹鑰醖齋襯築 )	不佳	2016-12-12
				Ranibizumab+Placebo	獵遞遞鑰齋繭衊糧夢築(醖鏇鏇淵齋鏇範鑰觸齋) = 觸糧簾襯簾憲糧齋範鹽憲壓淵觸夢築遞鹹範鹽 (齋窪觸範鹹鑰醖齋襯築 )
Phase 2b Study of Fovista (ARVO2016)	临床2期	Wet AMD	449	Fovista 0.3 mg with ranibizumab 0.5 mg	遞糧選窪夢夢齋餘糧艱(蓋齋簾鬱齋膚膚願範艱) = 積鹽衊淵廠糧壓鏇築壓襯鹹艱艱夢鬱簾夢繭齋 (觸衊鬱鏇鹽夢願鑰壓簾 ) 更多	积极	2016-05-01
				Fovista 1.5 mg with ranibizumab 0.5 mg	遞糧選窪夢夢齋餘糧艱(蓋齋簾鬱齋膚膚願範艱) = 餘醖夢鏇構蓋餘窪範膚襯鹹艱艱夢鬱簾夢繭齋 (觸衊鬱鏇鹽夢願鑰壓簾 ) 更多